406 related articles for article (PubMed ID: 29020350)
21. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
22. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
[TBL] [Abstract][Full Text] [Related]
23. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
25. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
[TBL] [Abstract][Full Text] [Related]
26. Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Ghosh S; Das NK; Mukherjee S; Mukhopadhyay D; Barbhuiya JN; Hazra A; Chatterjee M
Am J Trop Med Hyg; 2015 Oct; 93(4):767-9. PubMed ID: 26175030
[TBL] [Abstract][Full Text] [Related]
27. Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
Basher A; Rashid MM; Habibullah AM; Nath R; Akter D; Chowdhury IH; Azim A; Nath P; Faiz MA
Mymensingh Med J; 2019 Apr; 28(2):328-332. PubMed ID: 31086147
[TBL] [Abstract][Full Text] [Related]
28. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of blood based quantitative PCR as a molecular diagnostic tool for post kala-azar dermal leishmaniasis (PKDL).
Kumar A; Singh VK; Madhukar P; Tiwari R; Roy R; Rajneesh ; Mehrotra S; Sundar S; Kumar R
Mol Biol Rep; 2024 Jun; 51(1):716. PubMed ID: 38824237
[TBL] [Abstract][Full Text] [Related]
31. Active surveillance identified a neglected burden of macular cases of Post Kala-azar Dermal Leishmaniasis in West Bengal.
Sengupta R; Chaudhuri SJ; Moulik S; Ghosh MK; Saha B; Das NK; Chatterjee M
PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007249. PubMed ID: 30856178
[TBL] [Abstract][Full Text] [Related]
32. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Katara GK; Verma S; Salotra P
Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
[TBL] [Abstract][Full Text] [Related]
33. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
35. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
[TBL] [Abstract][Full Text] [Related]
36. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
[TBL] [Abstract][Full Text] [Related]
37. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
[TBL] [Abstract][Full Text] [Related]
38. Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.
Das VN; Ranjan A; Pandey K; Singh D; Verma N; Das S; Lal CS; Sinha NK; Verma RB; Siddiqui NA; Das P
Am J Trop Med Hyg; 2012 Jun; 86(6):959-61. PubMed ID: 22665600
[TBL] [Abstract][Full Text] [Related]
39. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
[TBL] [Abstract][Full Text] [Related]
40. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
